Lynparza approved in US for BRCAm prostate cancer
1 June 2023 Lynparza plus abiraterone approved in the US for the treatment ofBRCA-mutated metastatic castration-resistant prostate cancer Lynparza combination reduced the risk of disease progression or death by 76% vs. abiraterone alone First PARP inhibitor approved in combination with a new hormonal agent underscores clinically meaningful benefit of new treatment approach AstraZeneca and MSD's Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone has been approved in the US for the treatment of adult patients with deleterious or suspected